Figure 7
From: SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients
pSTAT6 levels in PBMCs after siRNA treatment against SHP-1. Cultured PBMCs from MS patients and normal subjects were stained with antibodies against the phosphorylated form of STAT6 (pSTAT6) or against SHP-1. The histogram overlays are labeled as follows: filled histogram for isotype control, solid line for normal subject, dashed line for MS patient, and dotted line for PBMCs treated with siRNA against SHP-1. (a) SHP-1 and (b) pSTAT6 expression in PBMCs of normal subjects, MS patients, and PBMCs treated with siRNA against SHP-1. (c) PBMCs were pretreated with scramble (nonspecific) siRNA and the levels of pSTAT6 were measured in MS patients (n=6) and normal subjects (n=6) before and after IL-4 treatment. (d) PBMCs were treated with siRNA against SHP-1 and the levels of pSTAT6 were measured both in MS patients (n=6) and normal subjects (n=6) before and after IL-4 treatment (*significance of P<0.05).
